The National Football League Alumni, Cancer Treatment Centers of America®, LabCorp® and Health Testing Centers Team Up to Offer Prostate Cancer Screenings in September

Nearly one in nine men, one in six African-American men, will be diagnosed with prostate cancer BOCA RATON, Fla., Aug. 16, 2018 /PRNewswire/ -- Prostate cancer is the second most common cancer among men. To raise awareness of the disease and the benefits of early screening, the NFL Alumni (NFLA),

LabCorp Announces 2018 Second Quarter Results and Updates 2018 Guidance

Q2 revenue of $2.9 billion , up 13% over $2.5 billion last year Q2 diluted EPS of $2.27 , up 28% from $1.78 last year; Q2 adjusted EPS of $2.98 , up 23% over $2.43 last year Q2 free cash flow of $280 million , up 16% over $241 million last year 2018 adjusted EPS guidance of $11.35 to $11.65 , up

Robert E. Mittelstaedt, Jr. to Retire from LabCorp Board of Directors and Current Board Member Adam H. Schechter to Assume Role of Lead Independent Director in 2019

BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 12, 2018-- LabCorp® (NYSE: LH) today announced that Robert E. Mittelstaedt, Jr., lead independent director, will retire from the LabCorp board of directors at the conclusion of his current term on May 9, 2019 , and that director Adam H.

Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 2, 2018-- LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject

LabCorp and Philips collaborate on digital pathology to enhance the efficiency of pathology diagnostics

BURLINGTON, N.C. and AMSTERDAM, June 28, 2018 /PRNewswire/ -- LabCorp® (NYSE: LH ), a leading global life sciences company that is deeply integrated in guiding patient care, and Royal Philips (NYSE: PHG , AEX: PHIA), a global leader in health technology, today announced a collaboration to further

LabCorp Launches Proprietary UltraQual® Multiplex PCR Assay for HCV, HIV-1, HIV-2 and HBV

FDA -approved test offered exclusively from LabCorp’s National Genetics Institute supports faster, more precise identification of viral agents in blood plasma used to manufacture cutting-edge biologic treatments BURLINGTON, N.C. --(BUSINESS WIRE)--Jun. 27, 2018-- LabCorp® (NYSE: LH), a leading

LabCorp Expands Drug Development Solutions with Acquisition of Sciformix

Sciformix extends Covance’s pharmacovigilance capabilities for post-approval safety solutions BURLINGTON, N.C. --(BUSINESS WIRE)--Jun. 11, 2018-- LabCorp® (NYSE: LH), a leading global life sciences company, announced today that it has acquired Sciformix Corporation , a scientific process

LabCorp is Scheduled to Present at the 38th Annual William Blair Growth Stock Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Jun. 5, 2018-- LabCorp® (NYSE: LH) today announced it will participate at the 38 th Annual William Blair Growth Stock Conference . LabCorp’s presentation is planned for Tuesday, June 12, 2018 at 12:10 PM (CT) . A live audio webcast of the presentation will be

LabCorp and Unilabs Collaborate to Expand Global Reach of Precision Medicine Capabilities to Serve Patients, Physicians and Pharma

Collaboration creates global laboratory network for the development and commercialization of companion diagnostics BURLINGTON, N.C. & GENEVA--(BUSINESS WIRE)--Jun. 1, 2018-- LabCorp® (NYSE: LH), a leading global life sciences company, and Unilabs, a leading European provider of clinical laboratory

LabCorp to Become a Preferred National Laboratory for Aetna

Agreement Expands Access to High-Quality, High-Value Laboratory Services for All Aetna Members HARTFORD, Conn. & BURLINGTON, N.C. --(BUSINESS WIRE)--May 25, 2018-- Aetna (NYSE: AET ) and LabCorp® (NYSE: LH) today extended and expanded their existing agreement, making LabCorp a preferred national